PMGC HOLDINGS INC. Revenue Not from Contract with Customer
PMGC HOLDINGS INC. (ELAB) reported Revenue Not from Contract with Customer of $139.15 thousand for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RevenueNotFromContractWithCustomer · last filed 2024-11-14
- PMGC HOLDINGS INC. revenue not from contract with customer for the quarter ending 2024-09-30 was $19.15K.
- PMGC HOLDINGS INC. revenue not from contract with customer for the quarter ending 2024-06-30 was $94.50K.
- PMGC HOLDINGS INC. revenue not from contract with customer for the quarter ending 2024-03-31 was $25.50K.
- PMGC HOLDINGS INC. revenue not from contract with customer for fiscal 2022 was $344.02K.
| Period end | Revenue Not from Contract with Customer 3 month | Revenue Not from Contract with Customer 6 month | Revenue Not from Contract with Customer 9 month | Revenue Not from Contract with Customer 12 month |
|---|---|---|---|---|
| 2024-09-30 | $19.15K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $113.65K derived: sum of 2 quarters · filed 2024-11-14 | $139.15K 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $94.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $120.00K 10-Q · filed 2024-08-14 | ||
| 2024-03-31 | $25.50K 10-Q · filed 2024-05-15 | |||
| 2023-06-30 | $73.55K 10-Q · filed 2024-08-14 | |||
| 2022-12-31 | $344.02K 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B |